Apremilast (CC-10004)

DRUG4 trials

Sponsors

Amgen, Virginia Clinical Research, Inc.

Conditions

Arthritis, PsoriaticBehcet SyndromeLichen PlanusPsoriasis

Phase 2

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

CompletedNCT00866359

AmgenBehcet Syndrome

Start: 2009-08-01End: 2012-05-01Updated: 2020-06-19

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

Virginia Clinical Research, Inc.Lichen Planus

Start: 2010-02-28End: 2012-02-29Target: 10Updated: 2010-01-01

Phase 3

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

CompletedNCT03701763

Start: 2018-12-19End: 2023-03-27Updated: 2024-12-16

Phase 4

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

CompletedNCT03747939

AmgenArthritis, Psoriatic

Start: 2018-12-31End: 2023-07-05Updated: 2026-09-11

Related Papers

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST.

2026-07-01

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial.

2026-05-14

Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial.

2025-11-01

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial

Annals of the Rheumatic Diseases2024-08-208 citations

Early Oligoarticular Psoriatic Arthritis Responds to Treatment With Apremilast: Week 16 Results From FOREMOST - a Phase 4 Randomized Controlled Trial

SKIN The Journal of Cutaneous Medicine2024-03-18

Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.

2024-01-2318 citations

Apremilast for the Treatment of Psoriasis in Special Areas in Pediatric Patients in the SPROUT Study

SKIN The Journal of Cutaneous Medicine2024-01-191 citations

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome

American Journal of Clinical Dermatology2023-06-1440 citations

Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study

New England Journal of Medicine2015-04-15229 citations